

OLZEP

Omeprazole USP



Presentation :

Olzep 20 Capsule : Each capsule contains omeprazole USP 20 mg in enteric coated Pellets.

Description :

Olzep (Omeprazole) a substituted benzimidazole, is an inhibitor of gastric acid secretion. Omeprazole inhibits secretion of gastric acid by blocking the hydrogen-potassium-adenosine triphosphatase enzyme system, the so-called 'proton pump' of the gastric parietal cell. It is effective for the treatment of gastric and duodenal ulcers and particularly for erosive reflux oesophagitis. Orally administered Olzep capsule is absorbed rapidly but to a variable extent. Following absorption Olzep capsule is almost completely metabolized and rapidly eliminated mostly in the urine. Although the elimination half-life from plasma is short, being reported to be 0.5 to 1.5 hours, its duration of action with regard to inhibition of acid secretion is much longer and it is suggested that its distribution to the tissues particularly to the gastric parietal cells accounts for this action. Olzep capsule is highly bound (about 95%) to plasma proteins.

Indication :

Benign gastric and duodenal ulcers including those complicating NSAID therapy, erosive reflux oesophagitis and for disorders associated with hypersecretion of gastric acid, such as the Zollinger-Ellison syndrome.

Dosage and Administration :

Benign gastric and duodenal ulcers including those complication NSAID therapy : 20 mg daily for 4 weeks in duodenal ulceration or 8 weeks in gastric ulceration, in severe cases the dose may be increased to 40 mg daily; long-term use is not recommended.

Healing of reflux oesophagitis : 20 mg daily for 4 weeks, followed by a further 4-8 weeks if not fully healed; 40 mg daily has been given for 8 weeks in reflux oesophagitis refractory to other treatment; may be continued at 20 mg daily.

Zollinger-Ellison syndrome : Initially 60 mg once daily; usual range 20-120 mg daily (above 80 mg in 2 divided doses). Larger doses of upto 180 mg daily in divided doses may be used or as prescribed by the physicians.

Contraindication :

There are no known contraindications to the use of Omeprazole.

Precaution and Warning :

Symptomatic response to therapy with Omeprazole does not preclude the presence of gastric malignancy. When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with Omeprazole is instituted as treatment may alleviate symptoms and delay diagnosis.

Side Effect :

Olzep is well tolerated. Nausea, diarrhea, abdominal colic, paresthesia, dizziness and headache have been stated to be generally mild and transient and not requiring a reduction in dosage.

Use in Pregnancy and Lactation :

Avoid in pregnancy unless there is no safer alternative. Breast feeding should be discontinued if the use of Omeprazole is considered essential.

Drug Interaction :

Omeprazole can delay the elimination of diazepam, phenytoin and warfarin. Reduction of warfarin or phenytoin dose may be necessary when omeprazole is added to treatment. There is no evidence of an interaction with theophylline, propranolol or antacids.

Storage :

Protect from light, store in dry place below 30° C.

Packs :

OLZEP 20 Capsule : Box contains 60 (6 x 10's) capsules in Alu-Alu blister packs.



Manufactured by:
Arges Life Science Limited
18/50, Sagorika Road,
Chattogram, Bangladesh.